A5050000895- Cutaneous Melanoma Detection and Management
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Epigenetics and DNA Methylation
- Melanoma and MAPK Pathways
- CAR-T cell therapy research
- Nonmelanoma Skin Cancer Studies
- Brain Metastases and Treatment
- Cancer Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- Click Chemistry and Applications
- Medical Imaging and Pathology Studies
- Viral Infectious Diseases and Gene Expression in Insects
- Cutaneous lymphoproliferative disorders research
- Virus-based gene therapy research
- Cancer Cells and Metastasis
- Glioma Diagnosis and Treatment
- Computational Drug Discovery Methods
- Renal cell carcinoma treatment
Peking University
2022-2025
Peking University Cancer Hospital
2022-2025
Atezolizumab plus bevacizumab has shown promising efficacy in advanced mucosal melanoma the multi-centre phase II study. This report updates 3-year survival outcomes and multi-omics analysis to identify potential response biomarkers.
Background OH2 is an oncolytic virus derived from herpes simplex type 2. A phase Ia/Ib clinical trial in China was conducted patients with unresected stage III–IV melanoma, the majority of whom had acral type, to assess safety and preliminary efficacy OH2. Methods The enrolled histologically confirmed unresectable III or advanced IV melanoma. In Ia, nine received single-dose treatment across three dose levels (10 6 , 10 7 8 CCID 50 /mL, where represents cell culture infectious 50%) while six...
Mucosal melanoma (MM) is an uncommon and aggressive malignant tumor, characterized by a scarcity of effective treatment options novel biomarkers. To develop biomarkers, total 89 MM tumor samples (including 50 cases in the discovery cohort 39 validation cohort) were collected from three medical centers. Targeted bisulfite sequencing RNA conducted cohort, Cox regression analysis was employed to evaluate DNA methylation (methyDNA) expression data. Our results revealed that, compared control...
Immune checkpoint inhibitors (ICIs) have provided new hope for melanoma patients, however, not all patients benefit. Furthermore, ICI-related therapies cause significant immune-related adverse events that adversely affect patient outcomes. Therefore, there is a pressing need reliable biomarkers to identify most likely benefit from these treatments. In this study, we employed an extracellular vesicles (EVs) protein expression array explore the longitudinal membrane profiles of plasma-derived...
9508 Background: Chemotherapy (temozolomide plus cisplatin) has been demonstrated to be a better adjuvant regimen compared high-dose interferon alpha-2b in resected Mucosal Melanoma (MuM) the pre-immunotherapy era. Yet present immunotherapy era, PD-1 inhibitor was recommended as standard therapy for Melanoma. No trial comparing chemotherapy with MuM had reported. we conducted this study determine efficacies of versus MuM. Methods: All patients (pts) received 200 mg/m 2 /day orally on days 1...
The proliferation marker Ki67 is associated with the progression and prognosis of melanoma. However, its prognostic impact on acral melanoma (AM) remains unclear.A total 314 AM patients were enrolled from a cohort 5758 at Peking University Cancer Hospital between 2006 2018. divided into high- low-expressing groups using cut-off value 30%. associations clinicopathologic characteristics as well survival analyzed. Cox proportional regression analysis was used to establish nomogram predict...
Abstract Mucosal melanoma exhibits limited responsiveness to anti-PD-1 therapy. However, a subgroup of mucosal melanomas, particularly those situated at specific anatomic sites like primary malignant the esophagus (PMME), display remarkable sensitivity treatment. The underlying mechanisms driving this superior response and DNA methylation patterns in have not been thoroughly investigated. We collected tumor samples from 50 patients with melanoma, including 31 PMME 19 non-esophageal (NEMM)....
Adjuvant chemotherapy has been shown to produce a favorable prognosis for patients with resectable mucosal melanoma (MM), resulting in the need stratification optimally select benefit from adjuvant therapy. This study analyzed Ki67 as potential index MM. Patients resected MM who received subsequent therapy Beijing Cancer Hospital between 2010 and 2018 were retrospectively enrolled analyzed. Relapse-free survival (RFS) melanoma-specific (MSS) curves used perform comparisons across different...
<p>Association of epigenetic features with prognosis in patients PMME. <b>A,</b> Comparison methylation levels selected DMRs (statistically significant multivariate analysis) among PMME, NEMM, and normal controls. <b>B,</b> Kaplan–Meier curve OS PMME stratified on the basis risk score derived from 7-DMR panel–based COX model. <b>C,</b> ROC depicting prediction performance model for survival status at 12, 18, 24 months, assessed using LOOCV. entire...
<p>Supplementary Figure S2. Diagram illustrating the genomic loci of 7-DMR panel.</p>
<p>Demographic and clinical characteristics of the patients with PMME NEMM included in study</p>
<p>More M1 and M2 macrophages, CD8<sup>+</sup> T cells, activated CD4<sup>+</sup> memory cells infiltrated in PMME compared with NEMM. <b>A,</b> Representative mIF image of macrophages. <b>B,</b> cells. SOX10, CD68, CD45RO, CD69 as markers for melanoma T, respectively. CD80 was employed to label while CD163 CD206 were used The ratio (<b>C</b>) (<b>D</b>) total macrophages PMME, NEMM, controls. positive rate...
<p>Association between <i>TERT</i> hypermethylation and immunotherapy responses. <b>A,</b> Significant immune-related pathways that were derived from GSEA of methylation-related genes when comparing PMME NEMM. <b>B,</b> normal controls. The infiltration level differences CD8<sup>+</sup> T cells (<b>C</b>) activated CD4<sup>+</sup> memory (<b>D</b>) in patients with...
<p>Increased immune cell infiltration and enriched immune-related pathways in PMME compared with NEMM. <b>A,</b> Comparison of infiltrated cells between <b>B,</b> Significantly identified through GSEA when comparing NEMM.</p>
<p>Association between <i>TERT</i> hypermethylation and immunotherapy responses. <b>A,</b> Significant immune-related pathways that were derived from GSEA of methylation-related genes when comparing PMME NEMM. <b>B,</b> normal controls. The infiltration level differences CD8<sup>+</sup> T cells (<b>C</b>) activated CD4<sup>+</sup> memory (<b>D</b>) in patients with...
<div>Abstract<p>Mucosal melanoma exhibits limited responsiveness to anti-PD-1 therapy. However, a subgroup of mucosal melanomas, particularly those situated at specific anatomic sites like primary malignant the esophagus (PMME), display remarkable sensitivity treatment. The underlying mechanisms driving this superior response and DNA methylation patterns in have not been thoroughly investigated. We collected tumor samples from 50 patients with melanoma, including 31 PMME 19...
<p>Supplementary Figure S2. Diagram illustrating the genomic loci of 7-DMR panel.</p>
<p>Supplementary Table 1. The univariate and multivariate COX analyses for OS associated DMRs in PMME patients.</p>
<p>PMME had a distinct epigenetic profile when compared with NEMM and normal controls. <b>A,</b> Schematic representation of the study design methodology. Methyl-seq, methylation sequencing; mIF, multiplex immunofluorescence; QC, quality control. <b>B,</b> The number hypermethylated hypomethylated DMRs between PMME, NEMM, <b>C,</b> unsupervised clustering in promoter regions PMME <b>D,</b> NEMM.</p>
<p>Role of <i>TERT</i> hypermethylation in PMME and its impact on immunologic signatures. <b>A,</b> Heat map depicting the association between hypermethylated genes immune cell infiltration PMME. <b>B,</b> Linear regression analysis demonstrating correlation methylation <b>C,</b> Comparison levels among PMME, NEMM, controls (*, <i>P</i> < 0.05; **, 0.01; ***, 0.001). <b>D,</b> expression tumors, controls.</p>
<p>Role of <i>TERT</i> hypermethylation in PMME and its impact on immunologic signatures. <b>A,</b> Heat map depicting the association between hypermethylated genes immune cell infiltration PMME. <b>B,</b> Linear regression analysis demonstrating correlation methylation <b>C,</b> Comparison levels among PMME, NEMM, controls (*, <i>P</i> < 0.05; **, 0.01; ***, 0.001). <b>D,</b> expression tumors, controls.</p>
<div>Abstract<p>Mucosal melanoma exhibits limited responsiveness to anti-PD-1 therapy. However, a subgroup of mucosal melanomas, particularly those situated at specific anatomic sites like primary malignant the esophagus (PMME), display remarkable sensitivity treatment. The underlying mechanisms driving this superior response and DNA methylation patterns in have not been thoroughly investigated. We collected tumor samples from 50 patients with melanoma, including 31 PMME 19...
<p>Supplementary Figure S1. PMME were generally associated with relatively lower levels of gene expression. (A) Vocanal plot and (B) unsupervised clustering the top 50 differentially expressed (DE) genes between normal control samples. (C) (D) DE NEMM.</p>